305 related articles for article (PubMed ID: 33238074)
1. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
Tomonari T; Sato Y; Tani J; Hirose A; Ogawa C; Morishita A; Tanaka H; Tanaka T; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Uchida K; Masaki T; Takayama T
Hepatol Res; 2021 Apr; 51(4):472-481. PubMed ID: 33238074
[TBL] [Abstract][Full Text] [Related]
2. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
[TBL] [Abstract][Full Text] [Related]
3. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and
Tomonari T; Sato Y; Tanaka H; Tanaka T; Fujino Y; Mitsui Y; Hirao A; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Kagiwada H; Kitazawa M; Fukui K; Horimoto K; Takayama T
Oncotarget; 2020 Jun; 11(26):2531-2542. PubMed ID: 32655838
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study.
Simmons DJ; Valerio SJ; Thomas DS; Healey MJ; Jiang Z; Levingston Mac Leod JM; Lin Y; Sah J
Adv Ther; 2024 Apr; 41(4):1711-1727. PubMed ID: 38443649
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.
Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Takayama T
JGH Open; 2020 Dec; 4(6):1135-1139. PubMed ID: 33319048
[TBL] [Abstract][Full Text] [Related]
6. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T; Kudo M; Ikeda K; Izumi N; Tateishi R; Ikeda M; Aikata H; Kawaguchi Y; Wada Y; Numata K; Inaba Y; Kuromatsu R; Kobayashi M; Okusaka T; Tamai T; Kitamura C; Saito K; Haruna K; Okita K; Kumada H
J Gastroenterol; 2020 Jan; 55(1):113-122. PubMed ID: 31720835
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
[TBL] [Abstract][Full Text] [Related]
9. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y
Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old.
Sato R; Moriguchi M; Iwai K; Tsuchiya S; Seko Y; Takahashi A; Kobayashi K; Ogasawara S; Watanabe S; Morimoto N; Kato N; Itoh Y; Aramaki T
Hepatol Res; 2022 Oct; 52(10):859-871. PubMed ID: 35921253
[TBL] [Abstract][Full Text] [Related]
13. Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.
Kuroda H; Oikawa T; Ninomiya M; Fujita M; Abe K; Okumoto K; Katsumi T; Sato W; Igarashi G; Iino C; Endo T; Tanabe N; Numao H; Fukuda S; Iijima K; Masamune A; Ohira H; Ueno Y; Takikawa Y
Liver Cancer; 2022 Jul; 11(4):383-396. PubMed ID: 35978602
[TBL] [Abstract][Full Text] [Related]
14. What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
Hiraoka A; Kumada T; Tada T; Kariyama K; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M
Liver Cancer; 2021 Apr; 10(2):115-125. PubMed ID: 33977088
[TBL] [Abstract][Full Text] [Related]
15. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
[TBL] [Abstract][Full Text] [Related]
16. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis.
Nakano M; Kuromatsu R; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Kamachi N; Koga H; Torimura T;
Hepatol Commun; 2020 Aug; 4(8):1218-1228. PubMed ID: 32766480
[TBL] [Abstract][Full Text] [Related]
17. Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B.
Kuwano A; Yada M; Tanaka K; Koga Y; Nagasawa S; Masumoto A; Motomura K
Cancer Diagn Progn; 2024; 4(2):111-116. PubMed ID: 38434920
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
[TBL] [Abstract][Full Text] [Related]
20. Real-World Lenvatinib
Kuo YH; Lu SN; Chen YY; Kee KM; Yen YH; Hung CH; Hu TH; Chen CH; Wang JH
Front Oncol; 2021; 11():737767. PubMed ID: 34760699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]